Microbot Medical®'s LIBERTY® Endovascular Robotic System Continues to Expand Market Visibility; Being Featured at an Industry Leading Innovation Conference

Core Insights - Microbot Medical Inc. announced that CEO Harel Gadot will participate as a panelist at The Surgical Disruptive Technology Summit, part of SAGES NBT Innovation Weekend, from February 19-21, 2026, in Houston, TX [1] - The summit aims to foster dialogue between industry and providers on innovations in surgical technology, focusing on minimally invasive interventions [2] Company Overview - Microbot Medical is a commercial stage medical device company dedicated to transforming endovascular procedures through advanced robotic technology [4] - The LIBERTY® Endovascular Robotic System is the first FDA cleared, single-use, remotely operated robotic solution designed for precision, efficiency, and safety in peripheral endovascular procedures [4] Product Features and Market Strategy - The LIBERTY System is designed to enhance access, safety, and clinical outcomes in vascular care, featuring remote interventions and precision navigation [2] - The company commenced limited market release of the LIBERTY system in late 2025 and plans a full market release at the Society of Interventional Radiology (SIR) conference in April 2026 [3] - LIBERTY's single-use, compact design aims to eliminate barriers to broader adoption of surgical robotics, positioning it as a new class of surgical robotics [3]